ArticleFrontiers in oncology2025
Development and validation of a prognostic model based on endoplasmic reticulum stress-related lncRNAs in breast cancer.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Breast cancer (BC), recognized as the most prevalent malignant tumor among women, has emerged as a critical global public health concern. Increasing evidence indicates that long non-coding RNAs (lncRNAs) are essential regulators in the initiation, development, and progression of BC, influencing tumor biology through diverse molecular mechanisms. Despite these advances, the specific prognostic significance of endoplasmic reticulum (ER) stress (ERS)-related lncRNAs in BC remains largely unexplored, and no comprehensive study has yet been reported in this context. Methods: In this study, we utilized high-throughput BC data from the TCGA database to identify ERS-related lncRNAs that are strongly associated with patient survival and prognosis. Based on these findings, we developed a risk model consisting of six ERS-related lncRNAs within the TCGA cohort, which demonstrated independent prognostic value for BC patients. We further examined the association of this model with clinical outcomes, the tumor microenvironment (TME), immune cell infiltration, and the predictive potential of immune checkpoint expression. In addition, we conducted functional analyses to explore the signaling pathways and biological processes regulated by ERS-related lncRNAs, providing new insights into their role in BC progression and prognosis. Results: The prognostic model constructed from six ERS-related lncRNAs demonstrated strong predictive performance, with AUC values of 0.702, 0.707, and 0.676 for estimating survival at 1, 3, and 5 years, respectively. Kaplan-Meier survival analyses further revealed that patients in the high-risk group exhibited significantly poorer overall survival (OS) compared to those in the low-risk group. Gene set enrichment analysis (GSEA) indicated that the prognostic model may be functionally linked to pathways involving the extracellular matrix (ECM) and focal adhesions. Among the six ERS-related lncRNAs, LMNTD2-AS1 was selected for functional validation, and experimental results demonstrated that its knockdown suppressed the proliferation, migration, and invasion abilities of breast cancer cells. Conclusions: Overall, our ERS-related lncRNA risk signature not only provides valuable prognostic insights but may also serve as a potential therapeutic target and biomarker to improve the management and treatment strategies for BC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.